Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04061044 | A Study to Evaluate the Long Term Safety of OTX-TP (Sustained Release Travoprost) Intracanalicular Insert | PHASE3 | COMPLETED | 40 | — | — | Jul 10, 2018 | Sep 22, 2020 | Jun 9, 2023 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| Treatment | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Ophthalmic Insert | DRUG | Travoprost, 0.32 mg |
Inclusion Criteria: * Had prior bilateral treatment and completion, through a minimum of week 12, of the OTX-16-002 trial * Are informed of the nature of the study and subject is able to comply with study requirements and visit schedule for one year * Have provided written informed consent, approve...